149 related articles for article (PubMed ID: 1814736)
1. Metabolic fate of 2,2-dimethylbutyryl moiety of simvastatin in rats: identification of metabolites by gas chromatography/mass spectrometry.
Uchiyama N; Kagami Y; Saito Y; Abe S; Ohtawa M; Hata S
Eur J Drug Metab Pharmacokinet; 1991; 16(3):189-96. PubMed ID: 1814736
[TBL] [Abstract][Full Text] [Related]
2. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry.
Morris MJ; Gilbert JD; Hsieh JY; Matuszewski BK; Ramjit HG; Bayne WF
Biol Mass Spectrom; 1993 Jan; 22(1):1-8. PubMed ID: 8431499
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.
Vickers S; Duncan CA; Vyas KP; Kari PH; Arison B; Prakash SR; Ramjit HG; Pitzenberger SM; Stokker G; Duggan DE
Drug Metab Dispos; 1990; 18(4):476-83. PubMed ID: 1976071
[TBL] [Abstract][Full Text] [Related]
4. Male-specific metabolism of simvastatin by rat liver microsomes.
Uchiyama N; Kagami Y; Saitoh Y; Ohtawa M
Chem Pharm Bull (Tokyo); 1991 Jan; 39(1):236-8. PubMed ID: 2049809
[TBL] [Abstract][Full Text] [Related]
5. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
Vickers S; Duncan CA; Chen IW; Rosegay A; Duggan DE
Drug Metab Dispos; 1990; 18(2):138-45. PubMed ID: 1971563
[TBL] [Abstract][Full Text] [Related]
6. Regioselectivity and stereoselectivity in the metabolism of HMG-CoA reductase inhibitors.
Vyas KP; Kari PH; Pitzenberger SM
Biochem Biophys Res Commun; 1990 Feb; 166(3):1155-62. PubMed ID: 2306236
[TBL] [Abstract][Full Text] [Related]
7. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse.
Vyas KP; Kari PH; Pitzenberger SM; Halpin RA; Ramjit HG; Arison B; Murphy JS; Hoffman WF; Schwartz MS; Ulm EH
Drug Metab Dispos; 1990; 18(2):203-11. PubMed ID: 1971574
[TBL] [Abstract][Full Text] [Related]
9. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
11. Studies on the metabolic inversion of the 6'chiral center of simvastatin.
Vickers S; Duncan CA
Biochem Biophys Res Commun; 1991 Dec; 181(3):1508-15. PubMed ID: 1764101
[TBL] [Abstract][Full Text] [Related]
12. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier.
Tsuji A; Saheki A; Tamai I; Terasaki T
J Pharmacol Exp Ther; 1993 Dec; 267(3):1085-90. PubMed ID: 8263769
[TBL] [Abstract][Full Text] [Related]
13. L-669,262, a potent HMG-CoA reductase inhibitor.
Joshua H; Schwartz MS; Wilson KE
J Antibiot (Tokyo); 1991 Mar; 44(3):366-70. PubMed ID: 2026562
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative.
Slater EE; MacDonald JS
Drugs; 1988; 36 Suppl 3():72-82. PubMed ID: 3076125
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacokinetics and practical applications of simvastatin.
Mauro VF
Clin Pharmacokinet; 1993 Mar; 24(3):195-202. PubMed ID: 8343198
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
17. Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Kim KH; Kang JY; Kim DH; Park SH; Park SH; Kim D; Park KD; Lee YJ; Jung HC; Pan JG; Ahn T; Yun CH
Drug Metab Dispos; 2011 Jan; 39(1):140-50. PubMed ID: 20962060
[TBL] [Abstract][Full Text] [Related]
18. Bioconversion of lovastatin to a novel statin by Amycolatopsis sp.
Zhuge B; Fang HY; Yu H; Rao ZM; Shen W; Song J; Zhuge J
Appl Microbiol Biotechnol; 2008 May; 79(2):209-16. PubMed ID: 18368405
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry.
Scoppola A; Maher VM; Thompson GR; Rendell NB; Taylor GW
J Lipid Res; 1991 Jun; 32(6):1057-60. PubMed ID: 1940620
[TBL] [Abstract][Full Text] [Related]
20. Generation of statin drug metabolites through electrochemical and enzymatic oxidations.
Khera S; Hu N
Anal Bioanal Chem; 2013 Jul; 405(18):6009-18. PubMed ID: 23760135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
